The early diagnosis of multiple endocrine neoplasia type 1 (MEN 1): A case report

Journal of Endocrinological Investigation

Volumn 27, Issue 9, 2004, Pages 878-882

  Tamagno, G ^a   De Carlo, Euge ^a   Martini, C ^a   Rubello, D ^b   Fallo, F ^a   Sicolo, N ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b S MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

Hyperprolactinemia; MEN1; Multiple endocrine neoplasia; Nuclear magnetic resonance; Octreoscan; Pituitary adenoma

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETREOTIDE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DNA SEQUENCE; ECHOGRAPHY; FEMALE; GENETIC ANALYSIS; HISTOLOGY; HUMAN; HYPERPARATHYROIDISM; HYPERPROLACTINEMIA; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE; PANCREAS RESECTION; PARATHYROID HYPERPLASIA; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION;

EID: 14544276518     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346285     Document Type: Article

References (28)

1. Arafah BM, Nasrallah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Related Cancer 2001, 8: 287-305.
2. Lubke D, Saeger W. Carcinomas of the pituitary: definition and review of the literature. Gen diagn path 1995, 141: 81-92.
3. Corbetta S, Pizzocaro A, Peracchi M, Beck-Peccoz P, Faglia G, Spada A. Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types. Clin Endocrinol (Oxf) 1997, 47: 507-12.
4. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 2001, 86: 5658-71.
5. Thakker RV. Multipe endocrine neoplasia. Horm Res 2001, 56 (Suppl 1): 67-72.
6. Kaczirek K, Prager G, Schindl M, et al. Multiple endocrine neoplasia 1 - Current recommendations for diagnosis and treatment. Wien Klin Wochenschr 2002, 114: 258-66.
7. Marsh D, Zori R. Genetic insights into familial cancers - update and recent discoveries. Cancer Lett 2002, 181: 125-64.
8. Carty SE, Helm AK, Amico JA, et al. The variable penetrance and spectrum of manifestations of multiple endocrine neoplasia type 1. Surgery 1998, 124: 1106-14.
9. Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab 2002, 87: 457-65.
10. Giordano A, Rubello D, Casara D. New trends in parathyroid scintigraphy. Eur J Nucl Med 2001, 28: 1409-20.
11. Zarnegar R, Brunaud L, Clark OH. Multiple endocrine neoplasia type I. Curr Treat Options Oncol 2002, 3: 35-48.
12. 99mMIBI in MEN type I. J Nucl Med 1997, 38: 1767-9.
13. Nguyen BD, Wang EA. Multiple endocrine neoplasia type 1: scintigraphic and magnetic resonance demonstration. Clin Nucl Med 1999, 24: 73-4.
14. Fidler JL, Johnson CD. Imaging of neuroendocrine tumors of the pancreas. Int J Gastrointest Cancer 2001, 30: 73-85.
15. van Eijck CH, Lamberts; SW, Lemaire LC, et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann Surg 1996, 224: 119-24.
16. Krausz Y, Bar-Ziv J, de Jong RBJ, et al. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors. Am J Gastroenterol 1998, 93: 66-70.
17. Skogseid B, Öberg K, Äkerström G, et al. Limited tumor involvement found at multiple endocrine neoplasia type 1 pancreatic exploration: can it be predicted by preoperative tumor localization? World J Surg 1998, 22: 673-8.
18. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997, 100: 2386-92.
19. Jacquet P, Ouafik L, Saveanu A, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999, 84: 3268-76.
20. Lamberts SWJ, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises. Eur J Endocrinol 2002, 146: 701-5.
21. Zatelli MD, Piccin D, Franceschetti P, et al. Dopamine-resistant invasive macroprolactinoma: from bench to bedside. J Endocrinol Invest 2002, 25 (Suppl 6): 18 (abstract).
22. Lamberts SWJ, Verleun T, Hofland L, Del Pozo E. A comparison between the effects of SMS201-995, bromocriptine and the combination of both drugs on hormone release by cultured pituitary tumor cells of acromegalic patients. Clin Endocrinol (Oxf) 1987, 27: 11-23.
23. Wagenaar AH, Harris AG, Van der Lely AJ, Lamberts SWJ. Dynamic of the acute effects of octreotide, bromocriptine and both drugs in combination on growth hormone secretion in acromegaly. Acta Endocrinol (Copenh) 1991, 125: 637-42.
24. Fredstorp L, Kutz K, Werner S. Treatment with octreotide and bromocriptine in patients with acromegaly: an open phamacodynamic interaction study. Clin Endocrinol (Oxf) 1994: 41: 103-8.
25. Flogstad AK, Halse J, Grass P, et al. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J Clin Endocrinol Metab 1994, 79: 461-5.
26. Abs R, Verhelst J, Master D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab 1998, 83: 374-8.
27. Barzon L, Pasquali C, Grigoletto C, Pedrazzoli S, Boscaro M, Fallo F. Multiple Endocrine Neoplasia type 1 and adrenal lesions. J Urol 2001, 166: 24-7.
28. Ringe D. Function by serendipity. Nature 2002, 415: 488-9.